All data are based on the daily closing price as of September 6, 2024
d
Dong-A Socio Holdings
000640.KO
88.22 USD
-3.89
-4.22%
Overview
Last close
88.22 usd
Market cap
551.42M usd
52 week high
96.32 usd
52 week low
60.16 usd
Target price
112.17 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
0.6
Price/Book Value
0.7115
Enterprise Value
971.12M usd
EV/Revenue
1.0636
EV/EBITDA
12.9284
Key financials
Revenue TTM
913.05M usd
Gross Profit TTM
208.87M usd
EBITDA TTM
115.56M usd
Earnings per Share
N/A usd
Dividend
1.05 usd
Total assets
2,034.24B usd
Net debt
N/A usd
About
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It develops DA-1241 for the treatment of type 2 diabetes and non-alcoholic steatohepatitis; DA-1726, an oxyntomodulin analogue to treat obesity; DA-1229, a dipeptidyl peptidase-4 inhibitor class treatment for type 2 diabetes; DA-8010, a muscarinic M3 receptor antagonist for the treatment of overactive bladder; DMB-3115, a biosimilar of Stelara and an inflammatory disease treatment; DA-3880 to treat anemia; STP0404, an HIV-1 treatment drug; and STP1002, an anti-cancer drug. The company also provides healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and derma business areas; CDMO services; imaging equipment and ENT workstation products; mineral water under the Cheonnyeonsu brand name; and IT and construction services. In addition, it produces glass bottles, PET, and corrugated cardboard boxes; engages in the foundry equipment, logistics, and food and beverage businesses. The company was founded in 1932 and is headquartered in Seoul, South Korea.